Posted by Michael Wonder on 28 Oct 2016
Update on proposed changes to 2nd & 3rd line anti-VEGF treatments for ophthalmic use
28 October 2016 - On 5 September 2016, PHARMAC consulted on a proposal to list ranibizumab (Lucentis) and aflibercept (Eylea) in Section H of the Pharmaceutical Schedule from 1 November 2016 for the treatment of patients with wet age-related macular degeneration.
This proposal arose following a request for proposals for the supply of anti-endothelial growth factor agents for ophthalmic use (primarily wet aged macular degeneration) issued on 5 May 2016.
PHARMAC received detailed consultation feedback on this proposal from a number of interested parties which we are taking some more time to carefully consider. This means a decision on the proposal as consulted upon will be delayed and therefore, for the avoidance of doubt, the proposed changes to listings will not occur on 1 November 2016.
PHARMAC expects a decision to be made, and subsequently notified, on the proposal before the end of 2016.
